Premium
Use of 111 in‐bleomycin for combining radiotherapy and chemotherapy on glioma‐bearing mice
Author(s) -
Hou DeYan,
Hoch Hans,
Johnston Gerald S.,
Tsou K. C.,
Farkas Raymond J.,
Miller Elizabeth E.
Publication year - 1985
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930290202
Subject(s) - medicine , bleomycin , glioma , radiation therapy , chemotherapy , group a , nuclear medicine , pathology , urology , cancer research
Mice bearing transplanted glioma received 0.9% NaCl, 0.1 mg of BLM, or 200–250 μ Ci of 111 In‐BLM (0.1 mg BLM) daily for 5 days intraperitoneally. After therapy, tumor sizes were in the order NaCl > BLM > 111 In‐BLM. On the 11th day after the first injection, tumor size (mm 3 ) in the 111 In‐BLM group was 1,220; in the BLM group, it was 2,310 (P < .025). After intratumor injection of a total dose of 0.1 mg of BLM/gm tumor weight, or of 1 mCi/gm tumor weight of 111 In‐BLM (carried by 0.1 mg of BLM/gm tumor weight), the tumor size decreased in the 111 In‐BLM group more than in the BLM group. On the 5th day after the 2nd dose therapy, the tumor size in the 111 In‐BLM group was 2,020; in the BLM group it was 4,220 (P < .05). Host weights for these two groups were similar. The necrotic area in the tumor was much greater in the 111 In‐BLM group than in the BLM group. These results suggest the use for radiotherapy and chemotherapy.